Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTG0MT6)

Molecule-Related Drug & Molecule List

Molecule-Related Drug List

Molecule Type:

DTT

DTP

DME

Drug Status:

Approved Drug(s)

Discontinued Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

3 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bimekizumab	DMR9TF1	Plaque psoriasis	EA90.0	Approved	[1]
Brodalumab	DMASDQ6	Plaque psoriasis	EA90.0	Approved	[2]
Ixekizumab	DMXW92T	Plaque psoriasis	EA90.0	Approved	[3]
------------------------------------------------------------------------------------

8 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABT-122	DM23UQ9	Psoriatic arthritis	FA21	Phase 2	[4]
CJM112	DMTSVJM	Acne vulgaris	ED80	Phase 2	[5]
CNTO-6785	DM6RQXB	Rheumatoid arthritis	FA20	Phase 2	[6]
COVA322	DM824EG	Psoriasis vulgaris	EA90	Phase 1/2a	[7]
SHR-1314	DMADNY3	Plaque psoriasis	EA90.0	Phase 1/2	[1]
ABBV-257	DMCZI8L	Rheumatoid arthritis	FA20	Phase 1	[8]
ALX-0761	DMJ8ACF	Psoriasis vulgaris	EA90	Phase 1	[7]
SCH-900117	DM7A6R5	Rheumatoid arthritis	FA20	Phase 1	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Clinical Trial Drug(s)

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG-4934	DMOI037	Arthritis	FA20	Discontinued in Phase 1	[10]
RO7040547	DMP0YNU	Asthma	CA23	Discontinued in Phase 1	[11]
------------------------------------------------------------------------------------

Molecule Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3	Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
4	DOI: 10.1136/annrheumdis-2015-eular.4042
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2.
7	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76.
10	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032677)
11	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.